Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
58
HAE Quote, Financials, Valuation and Earnings
Last price:
$80.13
Seasonality move
:
0.35%
Day range:
$79.51 - $80.22
52-week range:
$47.32 - $87.32
Dividend yield:
0%
P/E ratio:
23.34x
P/S ratio:
2.95x
P/B ratio:
4.41x
Volume:
152.7K
Avg. volume:
852.6K
1-year change:
3.36%
Market cap:
$3.7B
Revenue:
$1.4B
EPS (TTM):
$3.43
Analysts' Opinion
-
Consensus RatingHaemonetics Corp. has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $90.20, Haemonetics Corp. has an estimated upside of 12.74% from its current price of $80.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $74.00 representing 100% downside risk from its current price of $80.01.
Fair Value
-
According to the consensus of 7 analysts, Haemonetics Corp. has 12.74% upside to fair value with a price target of $90.20 per share.
HAE vs. S&P 500
-
Over the past 5 trading days, Haemonetics Corp. has underperformed the S&P 500 by -1.37% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Haemonetics Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Haemonetics Corp. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Haemonetics Corp. reported revenues of $327.3M.
Earnings Growth
-
Haemonetics Corp. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Haemonetics Corp. reported earnings per share of $0.81.
Enterprise value:
4.7B
EV / Invested capital:
2.25x
Price / LTM sales:
2.95x
EV / EBIT:
19.77x
EV / Revenue:
3.52x
PEG ratio (5yr expected):
0.55x
EV / Free cash flow:
18.25x
Price / Operating cash flow:
15.32x
Enterprise value / EBITDA:
13.33x
Gross Profit (TTM):
$730.2M
Return On Assets:
6.78%
Net Income Margin (TTM):
12.67%
Return On Equity:
19.39%
Return On Invested Capital:
7.99%
Operating Margin:
20.56%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1.2B | $1.4B | $1.3B | $345.5M | $327.3M | |
| Gross Profit | $630.2M | $695.4M | $730.2M | $178.9M | $183.4M | |
| Operating Income | $189.5M | $206M | $236.4M | $56.5M | $67.3M | |
| EBITDA | $283M | $315.5M | $350.7M | $85.7M | $95.5M | |
| Diluted EPS | $2.50 | $2.41 | $3.43 | $0.66 | $0.81 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $699.2M | $715.8M | $865.7M | $955.9M | $899.7M | |
| Total Assets | $1.8B | $1.9B | $2B | $2.5B | $2.4B | |
| Current Liabilities | $288.5M | $262.2M | $264.2M | $273.9M | $548.3M | |
| Total Liabilities | $1.1B | $1.1B | $1.1B | $1.6B | $1.6B | |
| Total Equity | $698.5M | $729M | $893.7M | $878.9M | $849.2M | |
| Total Debt | $780.8M | $817.7M | $762.2M | $1.2B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $261.1M | $84.9M | $289M | $48.8M | $111.3M | |
| Cash From Investing | -$94.9M | -$444.6M | -$62.8M | -$23.4M | -$30.5M | |
| Cash From Financing | -$57.9M | $304.8M | -$229.1M | -$74.8M | -$76.6M | |
| Free Cash Flow | $198M | $37.9M | $256.1M | $39.4M | $106.3M | |
HAE
Sector
Market Cap
$3.7B
$28M
Price % of 52-Week High
91.63%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-21.2%
-1.54%
1-Year Price Total Return
3.36%
-17.48%
Beta (5-Year)
0.301
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$80.29
200-day SMA
Buy
Level
$64.74
Bollinger Bands (100)
Buy
Level
48.03 - 74.63
Chaikin Money Flow
Buy
Level
89.8M
20-day SMA
Sell
Level
$81.90
Relative Strength Index (RSI14)
Buy
Level
57.48
ADX Line
Buy
Level
49.17
Williams %R
Buy
Level
-84.6065
50-day SMA
Buy
Level
$69.62
MACD (12, 26)
Buy
Level
2.43
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
20.3M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.3583)
Sell
CA Score
(Annual)
Level (-0.34)
Buy
Beneish M-Score
(Annual)
Level (-2.615)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (0.4336)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. The Plasma segment offers automated plasma collection and donor management software systems. The Blood Center segment provides solutions for donor collection centers' ability to acquire blood, filter blood, and separate blood components. The Hospital segment includes hemostasis management, cell salvage, and transfusion management services that help decision makers in hospitals optimize blood acquisition, storage, and usage in critical settings. The company was founded by Allen Latham, Jr. in 1971 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, HAE has received 3 Buy ratings 4 Hold ratings, and 0 Sell ratings. The HAE average analyst price target in the past 3 months is $90.20.
-
Where Will Haemonetics Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Haemonetics Corp. share price will rise to $90.20 per share over the next 12 months.
-
What Do Analysts Say About Haemonetics Corp.?
Analysts are divided on their view about Haemonetics Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Haemonetics Corp. is a Sell and believe this share price will drop from its current level to $74.00.
-
What Is Haemonetics Corp.'s Price Target?
The price target for Haemonetics Corp. over the next 1-year time period is forecast to be $90.20 according to 7 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is HAE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Haemonetics Corp. is a Hold. 4 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HAE?
You can purchase shares of Haemonetics Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Haemonetics Corp. shares.
-
What Is The Haemonetics Corp. Share Price Today?
Haemonetics Corp. was last trading at $80.13 per share. This represents the most recent stock quote for Haemonetics Corp.. Yesterday, Haemonetics Corp. closed at $80.01 per share.
-
How To Buy Haemonetics Corp. Stock Online?
In order to purchase Haemonetics Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HAE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HAE
Sector
P/E ratio
23.34x
23.89x
PEG ratio
0.55x
-0.01x
P/B ratio
4.41x
1.82x
Price / LTM sales
2.95x
1.60x
Growth Metrics
HAE
Sector
Revenue growth
-5.27%
4.62%
Earnings growth
22.93%
10.88%
Revenue (5-year growth)
6.6%
6.5%
Earnings forecast
$1.11
-$0.21
Profitability
HAE
Sector
Profitability FY 2024
$715.3M
$3.5M
Return on invested capital
7.99%
-31.77%
Return on assets
6.78%
-27.96%
Return on equity
19.39%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
HAE
Sector
Total cash
$296.4M
$26.3M
Short term investments
--
$25.7M
Total assets
$2.5B
$78M
Long term debt
$1.2B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
